APRINOIA Therapeutics
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A neuroscience company creating small molecule drugs and diagnostics for neurodegenerative diseases.
NeuroscienceDiagnostics
Technology Platform
Develops an integrated theranostic platform combining small molecule therapeutics and PET imaging diagnostics targeting proteinopathies in the brain.
Opportunities
The urgent, unmet need for effective neurodegenerative disease treatments creates potential for blockbuster products if clinical trials succeed.
Risk Factors
Extremely high clinical and regulatory risk due to the historical high failure rate of drugs targeting Alzheimer's and Parkinson's diseases.
Competitive Landscape
Competes in the difficult neurodegenerative disease space against other small biotechs and a handful of large pharma companies, with differentiation via its diagnostic pairing.